France's economy saw only a weak rebound after 2009 with real GDP growth rates of about two per cent in both 2010 and 2011 before slowing to a crawl with only 0.3 per cent growth in 2012. In comparison, Canada positively raced ahead, experiencing real GDP growth of 3.4, 3.0 and 1.9 per cent in 2010, 2011 and 2012 respectively.
With more and more attention focused on global environment and climate change, stakeholders (citizenry at large) are hungry for actionable solutions and real commitments. As companies start to more and more define their supply chains with sustainability as a core value, transparency and accountability in these efforts will be increasingly critical.
The tech wreck, the thickening border with the U.S. and the soaring loonie in the mid-2000's turned the attention of Canada's exporters to fast-growing emerging markets. In a relatively short time span, our trade with this rapidly-rising part of the global economy has risen from less than 5 per cent to almost 13 per cent of our merchandise exports.
Back in 2012, things looked grim for Canada's Big Pharma industry. A significant number of the industry's high-earning products were about to lose their patent protection, and face replacement by low-margin generics. But Canada's pharma industry, the eighth largest in the world, maintained its levels of innovation as well as formulating an innovative and successful business strategy.